Regen’s Approach Could Be Paradigm Shift in Supportive Oncology Care SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) today announced its ongoing efforts to expand the clinical development of HemaXellerate, its novel cellular therapy, to address chemotherapy-induced bone marrow suppression, a serious and common complication in cancer patients undergoing cytotoxic treatments. This represents potentially a market in excess of $1 billion per year in just the US. Following th ...

Core Insights - Adia Nutrition Inc. is finalizing in-network provider status with major health insurers, including Humana, Florida Blue, Cigna, Medicare, and Medicaid, to enhance patient access to its stem cell therapies [2][3][4] Group 1: Company Developments - The company is making significant progress in securing in-network status, which is crucial for making its regenerative therapies more accessible and affordable [3] - This milestone will allow Adia to deliver therapies for widely covered treatments, such as wound repair, to a broader patient base [3] - Adia has partnered with the PI Doctors Elite Community, connecting its labs with over 4,000 personal injury physicians nationwide [3] Group 2: Vision and Commitment - The CEO of Adia Nutrition expressed that joining major insurance networks will provide countless patients access to regenerative therapies, thereby increasing value for investors [4] - The company is dedicated to transforming healthcare by making regenerative solutions more accessible [4] Group 3: Licensing and Partnerships - Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its therapies are encouraged to reach out for strategic partnerships [5] Group 4: Company Overview - Adia Nutrition Inc. operates in two key divisions: a supplement division offering premium organic supplements and a medical division focused on advanced stem cell therapies, including Umbilical Cord Stem Cells and Autologous Hematopoietic Stem Cell Transplantation [6]

Company Overview - Adia Nutrition Inc. is a publicly traded company focused on regenerative medicine and personalized healthcare, with two key divisions: a supplement division and a medical division specializing in stem cell therapies [6]. Partnership and Market Access - Adia Labs has been selected as a preferred vendor for the PI Doctors Elite Community, gaining access to a network of over 4,000 personal injury physicians, which enhances its referral base for injury patients across the U.S. [1][4]. - The personal injury care industry is valued at approximately $50 billion annually, encompassing services such as orthopedic procedures, pain management, physical therapy, and rehabilitation [3]. Product Offerings - Adia Labs offers regenerative biologics, including AdiaVita and AdiaLink, aimed at supporting physicians in treating various injury-related conditions [3]. - These products may be covered by auto insurance for personal injury patients, streamlining the payment process compared to traditional health insurance [3]. Strategic Initiatives - The partnership with PI Doctors Elite complements Adia's recent initiatives, including expansion into the $25 billion wound care market and a national television campaign promoting Adia Med's regenerative solutions [2]. - Adia Labs is positioned to supply its products directly to a diverse network of healthcare providers, including orthopedic surgeons, chiropractors, neurologists, and pain specialists [4]. Future Opportunities - The company encourages clinic owners and healthcare practitioners to explore licensing the Adia Med name or integrating its regenerative therapies into their practices, indicating a strategy for expanding access to advanced stem cell solutions [5].

Core Insights - Adia Nutrition Inc. has launched its second nationwide television campaign to promote its regenerative stem cell therapies available at its Winter Park, Florida clinic [1][3][4] - The campaign aims to highlight the accessibility of advanced regenerative treatments in the U.S., addressing a market previously dominated by overseas options [3][4] - The company is positioned to lead in the $25 billion wound care market, showcasing its commitment to making high-quality regenerative therapies available domestically [3][6] Company Overview - Adia Nutrition Inc. operates in two key divisions: a supplement division offering organic products and a medical division focused on advanced stem cell therapies [10] - The company emphasizes the use of Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments [10] - Adia Med is currently an in-network provider with major insurers like UnitedHealthcare and Aetna, with plans to expand access through TRICARE [8] Market Position and Strategy - The new television campaign is designed to build the Adia brand and attract new patients, reinforcing the company's mission to provide accessible and affordable regenerative therapies [8] - The campaign is supported by favorable policy trends, such as Florida's SB1768 legislation, which recognizes the benefits of stem cell therapy, enhancing the legitimacy of regenerative medicine in the U.S. [6] - The company is open to strategic partnerships for licensing the Adia Med name and integrating its therapies into other practices, aiming to expand access to advanced stem cell solutions [9]

Core Insights - Apollo Biowellness, Inc. has announced the launch of a new self-stable biologic cosmetic line named Cielo Skin Care, which utilizes self-stabilized exosome and placental-based products derived from human tissue to enhance skin cell regeneration and anti-aging effects [1][3][4] Product Launch Details - The Cielo Skin Care line is set to launch in late Q3 and will be available in Q4 through major retail, e-commerce, direct-to-consumer marketing, social media influencers, and TV shopping outlets [4] - The company claims this is the first shelf-stable biologic skin care cosmetic, which is expected to significantly contribute to the growth of its business model alongside its existing Doctor and Med Spa brand, Evolutionary Biologics [4] Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, focus on the discovery, development, and marketing of products aimed at improving human health, positioning themselves as leaders in the field of Regenerative Medicine [5] - The company is currently working on marketing licensed patent-pending natural stem cell mobilizing agents and a dual acting all-natural diet aid designed to help control hunger [5]

Core Viewpoint - NurExone Biologic Inc. has successfully closed a private placement and announced promising preclinical imaging results for its lead product ExoPTEN, which shows potential for spinal cord repair following injury [1][10][14]. Company Developments - The company closed a non-brokered private placement of 1,258,072 units at C$0.62 per unit, raising gross proceeds of C$780,004.64, intended for working capital [10][11]. - NurExone is preparing for its first-in-human clinical trial of ExoPTEN, pending regulatory approval [4][14]. Product and Research Insights - Preclinical imaging analysis indicates that ExoPTEN-treated animals exhibited more organized spinal cord tissue compared to untreated controls, with 100% of higher-dose group animals regaining motor function [2][3]. - MRI-Diffusion Tensor Imaging (MRI-DTI) results show that treated spinal cords had greater structural integrity, with higher Fractional Anisotropy (FA) values and lower Mean Diffusivity (MD) values near the injury site, suggesting healthier tissue architecture [5][6][8][9]. - The imaging results support the neuroprotective and regeneration-promoting activity of ExoPTEN in spinal cord injury [3][15]. Market Context - Spinal cord injuries present significant healthcare and economic challenges, with current treatments primarily focusing on stabilization rather than tissue repair. ExoPTEN aims to address this unmet need by supporting nerve repair and restoring function [4][14]. - The market for spinal cord injury treatments is substantial, with NurExone's lead product positioned in a multi-billion-dollar market [14].

Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs [2] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [2] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [2] Pipeline and FDA Designations - Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [2] - The HLHS program has received three important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [2] - The Alzheimer's disease program has received two FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [2] Upcoming Events - Longeveron will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - The company's presentation is scheduled for September 8, 2025, from 4:00 to 4:30 p.m. ET, with a webcast available on the company's website [1]

Core Viewpoint - Apollo Biowellness, Inc. has received approval to file on OTCIQ and is actively pursuing multiple strategic initiatives to enhance its product offerings and market presence [1][6]. Group 1: Product Development - The company is in final negotiations with a NASDAQ-listed Israeli Bio-Tech manufacturer for the co-development of a shelf-stable biologic cosmetic named Ceilo Skin Care, set to launch in Q4 2025 [3]. - Apollo plans to introduce a unique Pet and Veterinarian Biologic product utilizing exosomes and placental products, targeting issues like arthritis and inflammation in pets, with a launch before the end of Q3 2025 [5]. Group 2: Strategic Partnerships - The company is negotiating with a large aesthetic company specializing in Laser Energy Devices for a potential merger or business combination to create a combined therapy company [4]. Group 3: Financial Strategy - Apollo is working with its debt holders and convertible note holders to restructure, refinance, or convert most positions to a preferred class of equity, aligning with management's growth financing plans for the next 12 months [6]. Group 4: Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, Inc., focus on discovering, developing, and marketing biologic-based products aimed at improving human health, positioning itself as a leader in Regenerative Medicine [7][8].

Core Insights - Beam Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BEAM-101, a genetically modified cell therapy aimed at treating sickle cell disease (SCD) [1][2] - The RMAT designation follows an earlier orphan drug designation and is expected to facilitate collaboration with the FDA as the company progresses towards a Biologics License Application (BLA) filing [2][4] - The BEACON Phase 1/2 trial has dosed 30 patients, with promising clinical data indicating robust increases in fetal hemoglobin and reductions in sickle hemoglobin [3][5] Company Overview - Beam Therapeutics is focused on developing precision genetic medicines using its proprietary base editing technology, which allows for precise genetic modifications without double-stranded breaks in DNA [7][8] - The company aims to create a fully integrated platform for gene editing, delivery, and manufacturing to provide long-term cures for serious diseases [7][8] Product Details - BEAM-101 is an investigational therapy that utilizes autologous CD34+ hematopoietic stem and progenitor cells, which are base-edited to enhance fetal hemoglobin production [5] - The therapy is designed to mimic naturally occurring variants that lead to increased fetal hemoglobin, potentially alleviating symptoms of SCD [5][6] Clinical Trial Insights - Updated clinical data from the BEACON trial presented at the EHA 2025 Congress showed durable increases in fetal hemoglobin and no vaso-occlusive crises reported post-engraftment [3][4] - The trial is ongoing, with additional data expected by the end of 2025, further supporting the potential of BEAM-101 as a transformative treatment for SCD [2][4]

Core Points - Longeveron Inc. has closed a public offering of 5,882,354 shares of Class A common stock at a price of $0.85 per share, with potential additional gross proceeds of up to $12.5 million from short-term warrants [1][3] - The company intends to use the net proceeds for ongoing clinical and regulatory development of laromestrocel, targeting conditions such as HLHS, Alzheimer's disease, and pediatric DCM, as well as for general corporate purposes [3][6] - H.C. Wainwright & Co. acted as the exclusive placement agent for this offering [2] Financial Details - The gross proceeds from the offering were approximately $5.0 million before deducting fees and expenses [3] - The short-term warrants have an exercise price of $0.85 per share and are immediately exercisable for a period of twenty-four months [1][3] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines, with its lead product being laromestrocel, an allogeneic mesenchymal stem cell therapy [6] - The company is pursuing four pipeline indications: HLHS, Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [6] - Laromestrocel has received multiple FDA designations, including Orphan Drug and Fast Track designations for HLHS, and Regenerative Medicine Advanced Therapy designation for Alzheimer's disease [6]